Short Interest in Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Declines By 72.6%

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a significant drop in short interest in the month of May. As of May 29th, there was short interest totaling 30,887 shares, a drop of 72.6% from the May 14th total of 112,539 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 560,221 shares, the short-interest ratio is presently 0.1 days.

Oncotelic Therapeutics Stock Down 1.1%

Shares of Oncotelic Therapeutics stock traded down $0.00 during midday trading on Thursday, hitting $0.05. The company’s stock had a trading volume of 265,307 shares, compared to its average volume of 287,926. The firm has a market capitalization of $23.47 million, a P/E ratio of 0.09 and a beta of -0.34. The stock has a 50-day simple moving average of $0.04 and a 200-day simple moving average of $0.06. The company has a quick ratio of 0.11, a current ratio of 0.11 and a debt-to-equity ratio of 0.01. Oncotelic Therapeutics has a 1-year low of $0.02 and a 1-year high of $0.11.

Oncotelic Therapeutics (OTCMKTS:OTLC) last issued its earnings results on Wednesday, April 15th. The company reported $0.59 EPS for the quarter.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics is a clinical?stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP?301), is an oncolytic adenovirus engineered to selectively replicate in telomerase?positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.